Reviewer’s report

Title: GlycA, a marker of protein glycosylation, is related to albuminuria and estimated glomerular filtration rate: the ELSA-Brasil study.

Version: 0 Date: 10 Apr 2017

Reviewer: Brad Astor

Reviewer's report:

Interesting analyses. A few issues need to be addressed.

1. How were the 5,050 participants selected out of the total of 15,105 in the cohort selected for this analysis?

2. Use of the terms "microalbuminuria" and "macroalbuminuria" is discouraged by the Kidney Disease: ImprovG Global Outcomes and other national and international groups. Other terms, such as "moderately increased albuminuria" should be used.

3. A histogram of the distribution of GlycA levels should be provided.

4. Analyses stratified by relevant subgroups (e.g., diabetes) may be quite informative.

5. Continuous analyses of the association between GlycA and albuminuria may be informative, as well.

6. Both the Introduction and Discussion should make a better case for the significance of examining this association between GlycA and albuminuria. What is it about albuminuria that makes this specific measure relevant for an inflammatory marker?

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

No

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes
Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review? 
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics

**Quality of written English**
Please indicate the quality of language in the manuscript:

Needs some language corrections before being published

**Declaration of competing interests**
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license ([http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/)). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal